<DOC>
	<DOC>NCT00635492</DOC>
	<brief_summary>Patients initiating injectable therapy for type 2 diabetes (insulin or exenatide) in usual clinical practice will be enrolled and followed up for two years in order to describe actual practice with regards to the time on initial treatment regime, whether treatment regimens are being modified, what treatment modifications are made, and clinical and patient-reported outcomes.</brief_summary>
	<brief_title>CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>are aged 18 or above diagnosed with type 2 diabetes have had a treatment decision made within the normal course of care to initiate either insulin or exenatide for the treatment of type 2 diabetes have not previously been treated with either insulin or exenatide are not simultaneously participating in another study which includes an investigational drug or procedure at study entry have been fully informed and given their written consent for use of their data have sufficient understanding of the primary language of their country such that they will be able to complete the questionnaires.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>insulin</keyword>
	<keyword>exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>